Search Videos and More
News
Tamoxifen May Boost PI3K Signaling to Increase Uterine Cancer Risk in Some Patients
Uterine cancers that developed in patients treated with tamoxifen had fewer PI3K pathway mutations and may have instead been driven by tamoxifen-induced PI3K pathway activation, according to results presented at the 2021 San Antonio Breast Cancer Symposium.
News
Dana-Farber Brigham Cancer Center Launches New Program for Women with Earliest Form of Breast Cancer
Dana-Farber Brigham Cancer Center is launching a new program designed to address the unique needs of women diagnosed with the earliest form of breast cancer. Nearly 60,000 women in the United States this year will be diagnosed with Ductal carcinoma in situ (DCIS), a type of breast cancer in which cancerous cells grow but are confined within the milk duct of the breast. The new program will offer DCIS patients outstanding clinical care delivered by Dana-Farber Brigham Cancer Center experts and will be the only such program in Greater Boston offering patients access to clinical trials specific to DCIS.
News
New Study Shows Young Women With Breast Cancer Who Opt for Mastectomies Report Lower Quality of Life
Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research by Dana-Farber Brigham Cancer Center.
Video
Breast Cancer Research at ESMO
Dana-Farber's Sara Tolaney, MD, MPH, provides insight on DESTINY-Breast09 trial highlighted at ESMO 2021.
News
Dosing Strategies Help Personalize Care in HER2+ Breast Cancer
Sara M. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.
Video
Updated Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Clinical Trials
Sara Tolaney, MD, MPH discusses updated standardized definitions for efficacy endpoints in adjuvant breast cancer clinical trials: STEEP Version 2.0.
News
Antibiotic Novobiocin Found to Kill Tumor Cells with DNA-Repair Glitch
An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute scientists shows.
Video
Study of SACI-IO for Triple Negative Metastatic Breast Cancer
Filipa Lynce, MD, provides an overview of a study at Dana-Farber Cancer Institute testing the safety and efficacy of sacituzumab govitecan (Trodelvy) with or without pembrolizumab (Keytruda) for patients with PD-L1-negative, triple-negative metastatic breast cancer.
Video
Trial 20-153: SACI-IO for Hormone Receptor Positive Metastatic Breast Cancer
Why test the combination of Trodelvy and pembrolizumab?
News
First Mammography Screening Guidelines Issued for Older Survivors of Breast Cancer
A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on the pros and cons of screening in survivors’ later years.